Aptose Biosciences (APTO) Competitors

Aptose Biosciences logo
$0.18 0.00 (-2.35%)
As of 01:05 PM Eastern

APTO vs. ELEV, DTIL, SRZN, PASG, OKYO, INKT, JATT, CRIS, CLDI, and CVM

Should you be buying Aptose Biosciences stock or one of its competitors? The main competitors of Aptose Biosciences include Elevation Oncology (ELEV), Precision BioSciences (DTIL), Surrozen (SRZN), Passage Bio (PASG), OKYO Pharma (OKYO), MiNK Therapeutics (INKT), JATT Acquisition (JATT), Curis (CRIS), Calidi Biotherapeutics (CLDI), and CEL-SCI (CVM). These companies are all part of the "biological products, except diagnostic" industry.

Aptose Biosciences vs.

Elevation Oncology (NASDAQ:ELEV) and Aptose Biosciences (NASDAQ:APTO) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their community ranking, analyst recommendations, valuation, dividends, media sentiment, risk, profitability, earnings and institutional ownership.

83.7% of Elevation Oncology shares are held by institutional investors. Comparatively, 26.6% of Aptose Biosciences shares are held by institutional investors. 8.1% of Elevation Oncology shares are held by company insiders. Comparatively, 1.3% of Aptose Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Elevation Oncology had 6 more articles in the media than Aptose Biosciences. MarketBeat recorded 6 mentions for Elevation Oncology and 0 mentions for Aptose Biosciences. Elevation Oncology's average media sentiment score of 1.19 beat Aptose Biosciences' score of 0.00 indicating that Elevation Oncology is being referred to more favorably in the media.

Company Overall Sentiment
Elevation Oncology Positive
Aptose Biosciences Neutral

Elevation Oncology has a beta of 1.31, meaning that its share price is 31% more volatile than the S&P 500. Comparatively, Aptose Biosciences has a beta of 0.88, meaning that its share price is 12% less volatile than the S&P 500.

Aptose Biosciences received 346 more outperform votes than Elevation Oncology when rated by MarketBeat users. However, 76.09% of users gave Elevation Oncology an outperform vote while only 62.46% of users gave Aptose Biosciences an outperform vote.

CompanyUnderperformOutperform
Elevation OncologyOutperform Votes
35
76.09%
Underperform Votes
11
23.91%
Aptose BiosciencesOutperform Votes
381
62.46%
Underperform Votes
229
37.54%

Elevation Oncology's return on equity of -59.73% beat Aptose Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Elevation OncologyN/A -59.73% -40.05%
Aptose Biosciences N/A -5,683.22%-300.44%

Elevation Oncology is trading at a lower price-to-earnings ratio than Aptose Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Elevation OncologyN/AN/A-$45.70M-$0.82-0.73
Aptose BiosciencesN/AN/A-$51.21M-$2.97-0.06

Elevation Oncology presently has a consensus target price of $7.20, indicating a potential upside of 1,098.00%. Aptose Biosciences has a consensus target price of $4.33, indicating a potential upside of 2,320.86%. Given Aptose Biosciences' higher probable upside, analysts clearly believe Aptose Biosciences is more favorable than Elevation Oncology.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Elevation Oncology
0 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
3.00
Aptose Biosciences
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00

Summary

Elevation Oncology beats Aptose Biosciences on 11 of the 14 factors compared between the two stocks.

Get Aptose Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for APTO and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

APTO vs. The Competition

MetricAptose BiosciencesBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$10.77M$2.99B$5.68B$9.00B
Dividend YieldN/A1.79%5.30%4.00%
P/E Ratio-0.0644.6688.4519.30
Price / SalesN/A393.91977.7577.07
Price / CashN/A192.7646.0638.77
Price / Book-0.943.975.084.98
Net Income-$51.21M-$41.02M$113.41M$221.97M
7 Day Performance-0.61%-4.11%-0.60%-0.11%
1 Month Performance-18.64%-2.11%3.24%2.52%
1 Year Performance-91.18%-7.56%21.49%19.58%

Aptose Biosciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
APTO
Aptose Biosciences
2.3191 of 5 stars
$0.18
-2.3%
$4.33
+2,320.9%
-91.0%$10.77MN/A-0.0631Analyst Forecast
ELEV
Elevation Oncology
2.7201 of 5 stars
$0.64
-7.4%
$7.20
+1,021.5%
-79.2%$37.90MN/A-0.7840Analyst Revision
Positive News
DTIL
Precision BioSciences
4.2503 of 5 stars
$4.83
-3.6%
$37.67
+679.8%
-58.4%$37.05M$75.10M80.51200
SRZN
Surrozen
3.3465 of 5 stars
$11.10
-4.3%
$38.50
+246.8%
+14.3%$36.08M$12.50M0.0080
PASG
Passage Bio
3.0957 of 5 stars
$0.58
flat
$7.75
+1,227.1%
-42.8%$36.01MN/A-0.50130
OKYO
OKYO Pharma
2.8628 of 5 stars
$1.04
-1.9%
$7.00
+573.1%
-35.7%$35.19MN/A0.007Analyst Forecast
Gap Down
INKT
MiNK Therapeutics
2.9122 of 5 stars
$8.23
-10.2%
$65.00
+689.8%
+9.5%$32.59MN/A-2.1130
JATT
JATT Acquisition
N/A$1.88
+6.8%
N/A-58.5%$32.43MN/A0.003High Trading Volume
CRIS
Curis
2.1227 of 5 stars
$3.39
-3.7%
$23.00
+578.3%
-69.1%$28.72M$10.02M-0.4360Upcoming Earnings
Gap Down
CLDI
Calidi Biotherapeutics
2.6681 of 5 stars
$1.06
+40.1%
$16.67
+1,469.4%
N/A$28.11M$50,000.000.0038Gap Down
High Trading Volume
CVM
CEL-SCI
N/A$0.37
-4.1%
N/A-85.4%$27.64MN/A-0.7343Analyst Forecast
News Coverage

Related Companies and Tools


This page (NASDAQ:APTO) was last updated on 2/11/2025 by MarketBeat.com Staff
From Our Partners